RightFit
RecruitingPhase not listed

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at treatment choices and satisfaction in adults with schizophrenia in the United States. It is for people newly prescribed xanomeline and trospium chloride (X/T) who plan to start taking it.

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be at least 18 years old on the study’s reference date.
  • Have a confirmed diagnosis of schizophrenia before that date. Schizophrenia is a mental illness that affects thinking and how a person sees reality.
  • Have a first prescription for X/T and plan to fill it and start treatment.
  • Sign and date an approved consent form agreeing to take part.
  • Agree to report how you are doing on an electronic device or on paper, in English or Spanish.
  • Speak English or Spanish.

Who can't join

  • Have taken part in a study that assigns a treatment or other health-related action within the past 30 days, or plan to take part in one when checked for eligibility.
  • Have used X/T before being checked for eligibility.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Aged ≥18 years at index date. * Have a confirmed diagnosis of schizophrenia before index date. * Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. * Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. * Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). * English or Spanish speaking. Exclusion Criteria: * Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. * Evidence of use of XT prior to time of eligibility screening.

Study sites (20)

CA

FL

IL

MA

MD

NC

NE

NJ

  • Hackensack Meridian Health - Carrier Clinic · Belle Mead, NJ 08502Stacy Doumas, Site 0001 · Study contactMore trials in Belle Mead

NY

OH

SC

TX